Multidisciplinary | Home

Malaysia
Search
Sign In

Multidisciplinary Search

Multidisciplinary

Multidisciplinary

Home News Diseases Conferences Special Reports Multimedia

Steroid for hand OA: A potential short-term treatment option?

Pearl Toh, 4 hours ago

Short-term treatment (6 weeks) with 10 mg prednisolone effectively reduces finger pain and improves function in patients who have painful hand osteoarthritis (OA) coupled with signs of inflammation, the HOPE* study has shown.

How COVID-19 has changed our lives

Elvira Manzano, 8 hours ago

The coronavirus has been spreading at a frantic pace, isolating families and snuffing out lives. As hunger and emotional contagion grip the nations, the hope of a containment also dims. No one has seen this enemy coming – the world has underestimated COVID-19.

Knee osteoarthritis heightens mortality risk

9 hours ago

Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).

Does recovered ejection fraction means recovered heart failure?

23 Mar 2020

Heart failure (HF) is a progressive condition where the heart is unable to pump enough blood to meet the body’s needs. Common causes of HF include ischaemic heart disease (IHD), hypertension, cardiomyopathy, diabetes and thyroid disorders. Patients with HF generally require lifelong treatment, but often ask if their medications may be stopped once their symptoms have improved. In this case study, Dato’ Dr Azmee Mohd Ghazi shares his clinical experience treating HF and the current evidence for HF therapy withdrawal.

From the throat to the gut: Essential learnings for physicians

10 Mar 2020

RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.

Advancing the role of SGLT-2 inhibitors and GLP-1 receptor agonists in the management of type 2 diabetes

10 Mar 2020

In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.

Updates from DECLARE-TIMI 58: Dapagliflozin offers cardiorenal benefit across the board in patients with T2DM

26 Feb 2020

At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.

CVOTs reinforce linagliptin’s cardiorenal safety profile in the management of T2D

24 Feb 2020

In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).

Doing it right from the get-go: The commitment of Sunway Medical Centre Velocity towards patient safety and satisfaction

Pank Jit Sin, 28 Jan 2020

The interest in healthcare and medicine is evident from companies in fields unrelated to healthcare venturing into the scene. With this interest is the boom of healthcare facilities, both clinics and hospitals, being set up in the country. As of end 2017, Malaysia counted 200 private hospitals with 14,799 beds. [https://www.export.gov/article?id=Malaysia-Healthcare, Accessed on 18 November]

The recent launch of Sunway Medical Centre Velocity (SMCV) coincides with the boom of hospitals established in the country. However, its founding should not be seen as jumping on the bandwagon. Rather, the hospital is a carefully planned and executed venture. MIMS spoke to SMCV’s Chief Executive Officer, Wilson Choo, to get his insights on the establishment of SMCV and his vision for SMCV in the short and long term.

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

Audrey Abella, 01 Apr 2020

A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine maintained viral suppression among virologically suppressed adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.

Adding cilostazol to other antiplatelet agents could reduce post-CAS restenosis risk

Roshini Claire Anthony, 31 Mar 2020

Adding cilostazol to other antiplatelet agents could potentially reduce in-stent restenosis (ISR) among patients with carotid artery stenosis who undergo carotid artery stenting (CAS), according to results of the CAS-CARE* trial presented at ISC 2020.

Apixaban outperforms warfarin regardless of prior stroke, TIA, or TE

Elvira Manzano, 31 Mar 2020

Apixaban outperformed warfarin in preventing ischaemic events regardless of prior stroke, transient ischaemic attack (TIA), or thromboembolic event (TE) in patients with atrial fibrillation (AF) with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), a prespecified secondary analysis of the AUGUSTUS trial has shown.

Every-2-month cabotegravir + rilpivirine feasible for HIV treatment

Pearl Toh, 27 Mar 2020

Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.

Losartan does not reduce inflammation, fibrosis in HIV patients

Audrey Abella, 27 Mar 2020

The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Starting oestradiol therapy soon after menopause may be good for heart health

Pearl Toh, 25 Mar 2020

Taking oestradiol therapy within 6 years after the start of menopause significantly delayed lipid plaque buildup in arterial walls — a leading cause of atherosclerosis, but such benefit was not seen when starting oestradiol a decade after menopause, reveals a secondary analysis of the ELITE* study presented at the recent EPI Lifestyle 2020 Scientific Sessions.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!